泊马度胺

化合物

泊马度胺(英语:Pomalidomide,商品名有PomalystImnovid)是一种含氮有机化合物,化学式为C13H11N3O4,可作为化疗药物[7],用于治疗多发性骨髓瘤AIDS相关的卡波西肉瘤[6]

泊马度胺
临床资料
商品名英语Drug nomenclaturePomalyst, Imnovid
AHFS/Drugs.comMonograph
MedlinePlusa613030
核准状况
怀孕分级
  • : X (高风险) [1]
给药途径By mouth
ATC码
法律规范状态
法律规范
药物动力学数据
生物利用度73% (at least)[8]
血浆蛋白结合率12–44%
药物代谢Liver (mostly CYP1A2- and CYP3A4-mediated; some minor contributions by CYP2C19 and CYP2D6)
生物半衰期7.5 hours
排泄途径Urine (73%), faeces (15%)
识别信息
  • 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
CAS号19171-19-8  checkY
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard英语CompTox Chemicals Dashboard (EPA)
ECHA InfoCard100.232.884 编辑维基数据链接
化学信息
化学式C13H11N3O4
摩尔质量273.25 g·mol−1
3D模型(JSmol英语JSmol
手性Racemic mixture
  • C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N
  • InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18) ☒N
  • Key:UVSMNLNDYGZFPF-UHFFFAOYSA-N ☒N

参考文献

  1. ^ Pomalidomide (Pomalyst) Use During Pregnancy. Drugs.com. 14 May 2020 [21 September 2020]. (原始内容存档于25 January 2021). 
  2. ^ Pomalidomide Medicianz/ Pomalimed/ Pomalidomide Medsurge (Medicianz Healthcare Pty Ltd). Therapeutic Goods Administration (TGA). 5 December 2022 [9 April 2023]. (原始内容存档于18 March 2023). 
  3. ^ Prescription medicines: registration of new chemical entities in Australia, 2014. Therapeutic Goods Administration (TGA). 21 June 2022 [10 April 2023]. (原始内容存档于10 April 2023). 
  4. ^ Product information. 
  5. ^ Imnovid 1 mg hard capsules - Summary of Product Characteristics (SmPC). (emc). 16 June 2020 [21 September 2020]. (原始内容存档于26 October 2020). 
  6. ^ 6.0 6.1 Pomalyst- pomalidomide capsule. DailyMed. 7 December 2017 [21 September 2020]. (原始内容存档于20 October 2020). 
  7. ^ 7.0 7.1 Imnovid EPAR. European Medicines Agency (EMA). 17 September 2018 [21 September 2020]. (原始内容存档于27 October 2020).  Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  8. ^ Imnovid 1 mg Hard Capsules. Summary of Product Characteristics. 5.2 Pharmacokinetic properties (PDF). Celgene Europe Ltd.: 22. [21 August 2016]. (原始内容存档 (PDF)于27 June 2016). 
  9. ^ Anvisa. RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control]. Diário Oficial da União. 2023-03-31 (2023-04-04) [2023-08-15]. (原始内容存档于2023-08-03) (巴西葡萄牙语).